Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions

The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes.

The Massachusetts biotechs follow Lenz Therapeutics and…
Click here to view original post